Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.

doi:10.1089/dna.2006.0573

Article

Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.

DNA and cell biology - 1 Mar 2007

Furukawa Mitsugi, Nagatomo Izumi, Kumagai Toru, Yamadori Tadahiro, Takahashi Ryo, Yoshimura Mana, Yoneda Tsutomu, Takeda Yoshito, Goya Sho, Matsuoka Hiroto, Kijima Takashi, Yoshida Mitsuhiro, Osaki Tadashi, Tachibana Isao, Greene Mark I, Kawase Ichiro

Abstract excerpt

Gefitinib-sensitive nonsmall cell lung cancers (NSCLC) are characterized by somatic mutations in the kinase domain of epidermal growth factor receptor (EGFR). The mutant EGFR forms are reported to mediate characteristic signal transduction pathways that are different from those mediated by the wi...

Topics

Animals
Binding Sites
COS Cells
Chlorocebus aethiops
Drug Resistance, Neoplasm
Endocytosis
Epidermal Growth Factor
ErbB Receptors
Gefitinib
Ligands

Mice

Mutation

Phosphorylation

Phosphotyrosine

Protein Kinase Inhibitors

Proto-Oncogene Proteins c-cbl

Quinazolines

Sequence Deletion

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.